Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 7/20 | 0.49 |
| ▸ | GCGR | P47871 | 5/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951057 | 0.81 | GCG (0.71) | GCGGCGR | |
| SCHEMBL9951477 | 0.81 | GCG (0.71) | GCGGCGR | |
| SCHEMBL9951606 | 0.81 | GCG (0.71) | GCGGCGR | |
| SCHEMBL9950967 | 0.80 | GCG (0.53) | GCGGCGRMCHR1 | |
| SCHEMBL9951367 | 0.80 | GCG (0.47) | GCGGCGRMCHR1FPR2 | |
| SCHEMBL9950714 | 0.79 | GCG (0.49) | GCGGCGRMCHR1 | |
| SCHEMBL21528709 | 0.77 | EPHX2 (0.36) | GCGRMCHR1KDM1AHDAC1RORC | |
| SCHEMBL21528712 | 0.77 | EPHX2 (0.36) | GCGRMCHR1KDM1AHDAC1RORC | |
| SCHEMBL9951480 | 0.77 | GCG (0.49) | GCGGCGRMCHR1 | |
| SCHEMBL9951615 | 0.74 | GCG (0.71) | GCGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | claimed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | claimed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | claimed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8933104-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933104-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329862-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329862-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329862-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885GCGR 2/4885MCHR1 242/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885GCGR 2/4885MCHR1 242/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885GCGR 2/4885MCHR1 242/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885GCGR 2/4885MCHR1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.